Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.

Autor:	Corcoran, N. M.1, Hovens, C. M.1, Michael, M.2, Rosenthal, M. A.3, Costello, A .J.1
Zdroj:	British Journal of Cancer. 8/10/2010, Vol. 103 Issue 4, p462-468. 7p. 4 Charts, 2 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu